“The announcement goes into effect on January 2022, but the MOH has stated that they will begin accepting CSDT format ahead of time.”

David Vo
General Manager
Asia Actual VietNam

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

VietNam Announces Increased Documentation Requirements

Published on: May 24th, 2021

On May 15, 2021, the VietNamese Ministry of Health (MOH) released new Guidance announcing Class B, C, and D devices will need to submit their applications in accordance with the ASEAN Common Submission Dossier Template (CSDT) format. The announcement goes into effect on January 2022 but the MOH has stated that they will begin accepting CSDT format ahead of time, greatly benefiting manufacturers that already have the CSDT documentation in order. Manufacturers will also need to show evidence of sufficient cybersecurity for products connected to the internet and all applications will need to be signed and stamped by a local license holder, like Asia Actual.

Leveraging Your CSDT Documentation

While the new process will require more documentation, allowing CSDT applications significantly benefits manufacturers with approvals in countries like Singapore and/or Malaysia (require CSDT). Manufacturers will also be able to submit most of their application in English (VietNamese also accepted) and will not need to submit VietNamese Technical Summaries and IFUs. Some IFUs may still need to be supplied in VietNamese, along with all devices still requiring a VietNamese sub-label. For the latest information on the VietNamese regulatory process, please see our Medical Device Registration page.

Outline of VietNam CSDT Table of Contents

1. Executive Summary

  1. An overview (introductory descriptive information on the medical device, the intended uses and indications for use of the medical device, any novel features and a synopsis of the content of the CSDT);
  2. Commercial marketing history;
  3. Intended uses and indications in labelling;
  4. List of regulatory approval or marketing clearance obtained;
  5. Important safety/performance related information.

2. Essential Principles and Evidence of Conformity with Declaration of Conformity

3. Device Description

  1. Device description & features
  2. Intended Use
  3. Indications
  4. User Manual/Instructions for Use
  5. Contraindications
  6. Warnings
  7. Precautions
  8. Potential adverse effects
  9. Alternative therapy
  10. Materials (VietNamese or English)
  11. Other Relevant Specifications
  12. Other Descriptive Information

4. Summary of Design Verification and Validation Documents (English or VietNamese)

  1. Pre-Clinical Studies
    1. Software verification and validation studies (if applicable)
    2. Medical equipment containing biological materials
  2. Preclinical studies of in vitro reagents, calibrators, and control materials
    1. Analytical Performance
    2. Stability
  3. Clinical Evidence
    1. Literature Review
    2. Clinical Experience Data (not from Clinical Studies)
    3. Clinical Studies

5. Device Labelling

  1. Samples of Labels on the Device and its Packaging
  2. User Manual/Instructions for Use

6. Risk Analysis (English or VietNamese)

7. Manufacturer Information (English or VietNamese)

Come Grow With Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in each market. Our commercialization experts can help you evaluate the VietNamese market and develop an optimal pricing strategy that can help you grow your sales in the 100-million-person market. Contact Asia Actual today with any questions or support requests.

Blog Posts

Australia SaMD Transition Deadline

Australia’s SaMD Regulatory Deadline

Beginning on November 1st, 2024, Australia's Therapeutic Goods Administration will implement new rules surrounding software as a medical device (SaMD). While some SaMD will require additional regulatory requirements, other SaMD will be exempted from some, or excluded completely, from the new regulations.
Thai FDA Documentation Exemptions for Concise and Full Regulatory Pathways

Thai FDA Regulatory Documentation Exemptions

March 12, 2024: the Thai FDA released draft guidance updating the list of required documentation for Full and Concise Evaluation. For manufacturers registering a medical device in Thailand, certain documents are no longer required.
Hong Kong MDD adds Singapore HSA to Reference Country List

Hong Kong MDD Adds Singapore as Reference Country

Starting April 2nd, 2024, the Hong Kong Medical Device Division (MDD) accepts, on a regular basis, the marketing approvals obtained from the the Health Sciences Authority (HSA) of Singapore as a support of compliance of medical device to the "Essential Principles of Safety and Performance of Medical Devices" (Technical Reference: TR-004) under MDACS.